Halozyme Therapeutics (NASDAQ:HALO) Given “Buy” Rating at HC Wainwright
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $72.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 19.03% from the stock’s current price. Several […]
Halozyme Therapeutics (NASDAQ:HALO – Get Free Report)‘s stock had its “buy” rating restated by equities research analysts at HC Wainwright in a report issued on Friday,Benzinga reports. They currently have a $72.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target suggests a potential upside of 19.03% from the stock’s current price. Several […]
